Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Available as a market-ready solution, ampli-D® can help nutraceutical brands fast-track innovation pipelines and quickly bring meaningful products targeting key health areas to market
dsm-firmenich, an innovator in nutrition, health, and beauty, has announced the approval of its ample-D® calcidiol monohydrate ingredient as a novel food in the EU by the European Commission.
Clinically proven in more than 15 human studies, ampli-D® is a calcifediol (calcidiol) ingredient that helps raise blood vitamin D levels 2.5 times faster and more effectively than conventional vitamin D3. Under the EU authorisation, ampli-D® is approved for a maximum daily dose of 10 µg in children over 11 years old and adults including pregnant and lactating women, and a maximum daily dose of 5 µg for children aged 3-10.
The approval marks a major milestone in dsm-firmenich’s ambition to bring breakthrough innovations to market and help consumers in the EU unlock the health benefits of the ‘sunshine vitamin’ more rapidly – which include support for immunity, healthy ageing, mobility and more. A five-year exclusive use period has been granted for dsm-firmenich to place ample-D® on the market.
Available as a Market-Ready Solution, ampli-D® can help nutraceutical brands fast-track innovation pipelines and quickly bring meaningful products targeting key health areas to market.